Premium
Vaccinations in patients with multiple sclerosis: review and recommendations
Author(s) -
Nesbitt Cassie,
Rath Louise,
Zhong Michael,
Cheng Allen C,
Butzkueven Helmut,
Wesselingh Robb,
Skibina Olga,
Monif Mastura,
Yeh Wei,
Brotherton Julia ML,
Reddel Stephen,
Van Der Walt Anneke
Publication year - 2021
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/mja2.51012
Subject(s) - library science , art history , management , history , computer science , economics
Multiple sclerosis (MS) is an autoimmune disorder treated with immunomodulatory or immunosuppressive diseasemodifying therapies (DMTs). Immunosuppression predisposes to infection risk, including opportunistic infections; a higher long term risk of some infectionrelated malignancies is also likely. Infections in patients with MS may result in increased relapses, functional decline and pregnancy complications.1 Immunisations play a critical role in preventing viral and bacterial infections, and in the setting of DMTs, they require careful and individualised planning from early in the treatment course. Here we provide an Australian perspective on vaccine safety and efficacy when given with DMTs.